Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/20016
DOI URL: http://dx.doi.org/10.21474/IJAR01/20016

RESEARCH ARTICLE

EXPLORING THE ANTIPSYCHOTIC POTENTIAL OF ALLOPURINOL: TARGETING PURINE METABOLISM IN SCHIZOPHRENIA TREATMENT

Parinda Parikh MD[1] and Dilbeste Sir MD[2]

1. Psychiatry Department, Weill Cornell Medical School, White Plains, New York, USA.
2. Second Arc Psychiatric Associates, White Plains, New York, USA.

Manuscript Info

Manuscript History
Received: 07 October 2024
Final Accepted: 09 November 2024
Published: December 2024

Keywords:-
Allopurinol, Schizophrenia, Purinergic System, Adenosine, Oxidative Stress

Abstract

The purinergic system, characterized by the signaling pathways mediated by purines such as adenosine and ATP, plays a significant role in the pathophysiology of schizophrenia. Recent research has highlighted the potential of allopurinol, a xanthine oxidase inhibitor traditionally used to manage hyperuricemia and gout, as an adjunctive treatment for schizophrenia. Allopurinol's mechanism of action involves the modulation of adenosine metabolism, which may help restore neurotransmitter balance, particularly in the dopaminergic and glutamatergic systems involved in schizophrenia. Clinical studies show mixed results about the effectiveness of allopurinol. Some trials report that it significantly improves psychotic symptoms and cognitive problems, while others have inconclusive results. The variability in findings may be attributed to differences in study design, patient populations, and the specific symptoms assessed. allopurinol may help treat schizophrenia by reducing oxidative stress and inflammation in the brain. Its antioxidant properties support its potential as a useful therapy. Despite generally favorable safety and tolerability profiles, the long-term effects of allopurinol in psychiatric populations require further investigation. Overall, while allopurinol shows promise for improving treatment outcomes in schizophrenia, further studies are necessary to clarify its efficacy, optimal dosing, and its role in combination with existing antipsychotic therapies.

Introduction:-

Role of the Purinergic System in Schizophrenia

The purinergic system, characterized by the signaling actions of purines such as adenosine and ATP, plays a crucial role in various physiological processes within the central nervous system (CNS). This system is involved in neurotransmission, neuromodulation, and the regulation of neuroinflammatory responses, essential for maintaining homeostasis in neural environments (Steen et al., 2019; Lindberg et al., 2015; Burnstock, 2010). The purinergic receptors, classified into P1 (adenosine receptors) and P2 (ATP receptors), mediate a wide range of cellular functions, including synaptic plasticity, neuronal excitability, and glial cell activity (Cheffer et al., 2017; Zarrinmayeh&Territo, 2020; Puchałowicz et al., 2014). Due to their extensive role in neuronal signaling, changes in purinergic signaling pathways have been linked to several psychiatric disorders, such as schizophrenia, bipolar

Corresponding Author:- Parinda Parikh MD
Address:- Psychiatry Department, Weill Cornell Medical School, White Plains, New York, USA.

disorder, and depression. (Cheffer et al., 2017; Lindberg et al., 2015; Huang et al., 2021). Research has increasingly highlighted the relationship between purinergic dysfunction and psychiatric conditions. For instance, studies have shown that abnormalities in purinergic signaling may contribute to the pathophysiology of schizophrenia, where dysregulation of ATP and adenosine levels can affect neurotransmitter systems and lead to cognitive deficits and mood disturbances (Alnafisah et al., 2022; Lindberg et al., 2015; Huang et al., 2021). Furthermore, the purinergic system's role in mood regulation suggests that it may act as a common pathway linking various psychiatric disorders.Research indicates that purinergic signaling is altered in individuals with bipolar disorder, as fluctuations in uric acid levels—a marker of purinergic activity—have been observed during manic episodes. (Salvadore et al., 2010; Oliveira et al., 2018; Gonçalves et al., 2022). This connection highlights the potential of the purinergic system as a therapeutic target for treating mood disorders and schizophrenia, as modulation of purinergic receptors may offer new opportunities for intervention (Calker et al., 2019; Lindberg et al., 2015; Huang et al., 2021).

Role of Allopurinol in Schizophrenia

Allopurinol, a xanthine oxidase inhibitor primarily used to manage hyperuricemia and gout, has garnered attention in psychiatric research for its potential applications in treating schizophrenia and related disorders.The drug functions by inhibiting the conversion of hypoxanthine and xanthine to uric acid, thereby reducing serum uric acid levels and potentially reducing oxidative stress in the brain (Lara et al., 2000; Oertel& Cala, 2006). The rationale behind exploring allopurinol's efficacy in schizophrenia is based on the purinergic dysfunction hypothesis, which suggests that disturbances in purinergic signaling may contribute to the pathophysiology of various psychiatric disorders, including schizophrenia (Akhondzadeh et al., 2006; Dr et al., 2001). The purinergic system, which involves purines such as ATP and adenosine signaling, plays a significant role in neurotransmission and neuroinflammation. Schizophrenia involves changes in purinergic signaling that modulate dopaminergic and glutamatergic pathways, which are crucial for psychotic symptoms. (Muir et al., 2008; Shen et al., 2012). Allopurinol can enhance adenosinergic signaling by indirectly raising adenosine levels by inhibiting xanthine oxidase. This enhancement shows neuroprotection and modulates neurotransmitter release.(Ghisolfi et al., 2002; Lintunen et al., 2021). Allopurinol may improve cognitive and negative symptoms of schizophrenia. These symptoms often do not respond well to regular antipsychotic treatments.(Zhang et al., 2016; Oertel& Cala, 2006). Research on allopurinol's use in treating schizophrenia shows promising results. A study that used a double-blind, randomized, and placebo-controlled design found that allopurinol, when added to standard antipsychotic treatment, significantly improved symptoms in patients with treatment-resistant schizophrenia. (Gibney et al., 2014; Bartoli et al., 2017). These findings support earlier reports that allopurinol may be effective in managing aggressive and self-injurious behaviors in patients with schizophrenia. (Dutra et al., 2010; Liang et al., 2010). Furthermore, allopurinol's favorable safety profile and tolerability make it a good option for adjunctive therapy in this population (Salvadore et al., 2010; Demirci et al., 2014). Moreover, the relationship between uric acid levels and psychiatric symptoms is noteworthy. Elevated uric acid levels have been associated with increased oxidative stress, which may exacerbate symptoms in individuals with schizophrenia (Liang et al., 2010; Machado-Vieira et al., 2010). Allopurinol can reduce oxidative stress and enhance brain health by decreasing uric acid levels, potentially leading to better clinical outcomes (Lintunen et al., 2021; Shen et al., 2012). This connection shows how allopurinol affects biochemical processes related to schizophrenia and other mood disorders.

Discussion:-

Research into using allopurinol as an additional treatment for schizophrenia has increased in recent years. This interest is mainly due to its ability to influence the purinergic system and reduce oxidative stress. Both of these factors are believed to play essential roles in the development of schizophrenia. Allopurinol, a xanthine oxidase inhibitor, primarily functions to lower uric acid levels. Clinical studies on allopurinol's effectiveness in treating schizophrenia have shown mixed results. For instance, a randomized controlled trial by Weiser et al. demonstrated that allopurinol, when added to standard antipsychotic treatment, resulted in significant improvements in psychotic symptoms among patients with schizophrenia or schizoaffective disorder (Weiser et al., 2012). This finding supports the adenosine hypothesis of schizophrenia. This hypothesis suggests that issues with adenosine signaling may play a role in the symptoms of the disorder. (Boison et al., 2012; Singer & Yee, 2023). Allopurinol's ability to increase extracellular adenosine levels could help restore balance in neurotransmitter systems, particularly those involving dopamine and glutamate, which are often involved in schizophrenia (Shen et al., 2012). Conversely, other studies have reported less favorable outcomes. For example, a systematic review and meta-analysis by Hirota and Kishi found that while some trials indicated a positive effect of allopurinol on schizophrenia symptoms, the overall evidence was inconclusive, suggesting that more studies are needed to establish its efficacy (Hirota&Kishi, 2013). Furthermore, the differences in study results may come from variations in study design, patient populations, and the

specific symptoms being measured. The ways that allopurinol may affect schizophrenia are still being discussed. Some researchers say that its main effect might come from its antioxidant properties. This could help reduce oxidative stress linked to the disorder(Mijailović et al., 2022; Boison, 2011). Elevated uric acid levels have been linked to increased oxidative stress, and by lowering these levels, allopurinol may help reduce neuroinflammation and improve overall brain health (Salvadore et al., 2010). However, the relationship between uric acid, oxidative stress, and schizophrenia remains complex and not fully understood.Some studies suggest uric acid may have neuroprotective effects in specific contexts (Mijailović et al., 2022). Moreover, the safety and tolerability of allopurinol in psychiatric populations have been generally favorable, with reports indicating that it may reduce the incidence of extrapyramidal symptoms associated with antipsychotic medications (Fan et al., 2012; Carr et al., 2017).

Conclusion:-

In summary, there is increasing evidence that allopurinol can help treat schizophrenia, but the results are not always consistent. The differences in study results show that more research is needed to understand the drug's efficacy, optimal dosing, and long-term safety in this context. As the understanding of the purinergic system and its role in schizophrenia continues to evolve, allopurinol may be a promising treatment option, especially for patients who do not respond to standard treatments. Future studies should address the existing knowledge gaps and explore the potential of allopurinol in combination with other pharmacological and non-pharmacological interventions.

References:-

1. Akhondzadeh, S., Milajerdi, M., Amini, H., & Tehrani-Doost, M. (2006). Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disorders, 8(5p1), 485-489. https://doi.org/10.1111/j.1399-5618.2006.00363.x
2. Alnafisah, R., Lundh, A., Asah, S., Hoeflinger, J., Wolfinger, A., Hamoud, A., … & O'Donovan, S. (2022). Altered purinergic receptor expression in the frontal cortex in schizophrenia. Schizophrenia, 8(1). https://doi.org/10.1038/s41537-022-00312-1
3. Assmann, C., Apolloni, S., Ignácio, Z., &Bagatini, M. (2022). Editorial: purinergic signaling and neuroinflammation. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1113063
4. Bartoli, F., Crocamo, C., Clerici, M., &Carrà, G. (2017). Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials. The British Journal of Psychiatry, 210(1), 10-15. https://doi.org/10.1192/bjp.bp.115.180281
5. Boison, D. (2011). Modulators of nucleoside metabolism in the therapy of brain diseases. Current Topics in Medicinal Chemistry, 11(8), 1068–1086. https://doi.org/10.2174/156802611795347609
6. Boison, D., Singer, P., Shen, H., Feldon, J., & Yee, B. (2012). Adenosine hypothesis of schizophrenia – opportunitiesfor pharmacotherapy. Neuropharmacology, 62(3), 1527–1543. https://doi.org/10.1016/j.neuropharm.2011.01.048
7. Carr, C., Straley, C., & Baugh, T. (2017). Allopurinol for the treatment of refractory aggression: a case series. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 37(6), 748–754. https://doi.org/10.1002/phar.1943
8. Calker, D., Biber, K., Domschke, K., &Serchov, T. (2019). The role of adenosine receptors in mood and anxiety disorders. Journal of Neurochemistry, 151(1), 11-27. https://doi.org/10.1111/jnc.14841
9. Cheffer, A., Castillo, A., Corrêa-Velloso, J., Gonçalves, M., Naaldijk, Y., Nascimento, I., … & Ulrich, H. (2017). Purinergic system in psychiatric diseases. Molecular Psychiatry, 23(1), 94-106. https://doi.org/10.1038/mp.2017.188
10. Demirci, K., Özcankaya, R., Yılmaz, H., Yiğit, A., Uğuz, A., Karakuş, K., … &Akpınar, A. (2014). Paliperidone regulates intracellular redox system in rat brain: role of purine mechanism. Redox Report, 20(4), 170-176. https://doi.org/10.1179/1351000214y.0000000122
11. Dr, L., Mg, B., Ghisolfi, E., Mi, L., Belmonte-de-Abreu, P., & Souza, D. (2001). Allopurinol augmentation for poorly responsive schizophrenia. International Clinical Psychopharmacology, 16(4), 235-237. https://doi.org/10.1097/00004850-200107000-00008
12. Dutra, G., Ottoni, G., Lara, D., & Bogo, M. (2010). Lower frequency of the low activity adenosine deaminase allelic variant (ada1*2) in schizophrenic patients. Brazilian Journal of Psychiatry, 32(3), 275-278. https://doi.org/10.1590/s1516-44462010005000003

13. Fan, A., Berg, A., Bresee, C., Glassman, L., & Rapaport, M. (2012). Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disorders, 14(2), 206-210. https://doi.org/10.1111/j.1399-5618.2012.01001.x
14. Ghisolfi, E., Prokopiuk, A., Becker, J., Ehlers, J., Belmonte-de-Abreu, P., Souza, D., … & Lara, D. (2002). The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects. Neuropsychopharmacology. https://doi.org/10.1016/s0893-133x(02)00337-8
15. Gibney, S., Fagan, E., Waldron, A., O'Byrne, J., Connor, T., & Harkin, A. (2014). Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behavior. The International Journal of Neuropsychopharmacology, 17(06), 917–928. https://doi.org/10.1017/s1461145713001673
16. Gonçalves, M., Andrejew, R., &Gubert, C. (2022). The purinergic system as a target for the development of treatments for bipolar disorder. CNS Drugs, 36(8), 787-801. https://doi.org/10.1007/s40263-022-00934-0
17. Hirota, T. and Kishi, T. (2013). Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophrenia Research, 149(1-3), 88–95. https://doi.org/10.1016/j.schres.2013.06.038
18. Huang, Z., Xie, N., Illéš, P., Virgilio, F., Ulrich, H., Semyanov, A., … & Tang, Y. (2021). From purines to purinergic signaling: molecular functions and human diseases. Signal Transduction and Targeted Therapy, 6(1). https://doi.org/10.1038/s41392-021-00553-z
19. Lara, D., Belmonte-de-Abreu, P., & Souza, D. (2000). Allopurinol for refractory aggression and self-inflicted behavior. Journal of Psychopharmacology, 14(1), 81–83. https://doi.org/10.1177/026988110001400112
20. Liang, C., Yang, F., Chiang, K., & Ho, P. (2010). Allopurinol for treatment-resistant schizophrenia and epilepsy: a case report. Pharmacopsychiatry, 43(06), 233-234. https://doi.org/10.1055/s-0030-1254092
21. Linden, N., Onwuanibe, A., &Sandson, N. (2014). Rapid resolution of psychotic symptoms in a patient with schizophrenia using allopurinol as an adjuvant. Clinical Schizophrenia & Related Psychoses, 7(4), 231-234. https://doi.org/10.3371/csrp.lion.020113
22. Lindberg, D., Shan, D., Ayers-Ringler, J., Oliveros, A., Benitez, J., Prieto, M., … & Choi, D. (2015). Purinergic signaling and energy homeostasis in psychiatric disorders. Current Molecular Medicine, 15(3), 275–295. https://doi.org/10.2174/1566524015666150330163724
23. Lintunen, J., Lähteenvuo, M., Tiihonen, J., Tanskanen, A., & Taipale, H. (2021). Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia. NPJ Schizophrenia, 7(1). https://doi.org/10.1038/s41537-020-00135-y
24. Machado-Vieira, R., Salvadore, G., Diazgranados, N., Ibrahim, L., Latov, D., Wheeler-Castillo, C., … & Zarate, C. (2010). New therapeutic targets for mood disorders. The Scientific World Journal, 10, 713-726. https://doi.org/10.1100/tsw.2010.65
25. Mijailović, N., Vesić, K., &Borovcanin, M. (2022). The influence of serum uric acid on the brain and cognitive dysfunction. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.828476
26. Muir, S., Harrow, C., Dawson, J., Lees, K., Weir, C., Sattar, N., … & Walters, M. (2008). Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke. Stroke, 39(12), 3303–3307. https://doi.org/10.1161/strokeaha.108.519793
27. Oertel, M. and Cala, S. (2006). Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia. Annals of Pharmacotherapy, 40(12), 2200-2204. https://doi.org/10.1345/aph.1h222
28. Oliveira, P., Santos, V., Coroa, M., Ribeiro, J., & Madeira, N. (2018). Serum uric acid as a predictor of bipolarity in individuals with a major depressive episode. Bipolar Disorders, 21(3), 235-243. https://doi.org/10.1111/bdi.12708
29. Puchałowicz, K., Tarnowski, M., Baranowska-Bosiacka, I., Chlubek, D., &Dziedziejko, V. (2014). P2x and p2y receptors—role in the pathophysiology of the nervous system. International Journal of Molecular Sciences, 15(12), 23672-23704. https://doi.org/10.3390/ijms151223672
30. Salvadore, G., Viale, C., Luckenbaugh, D., Zanatto, V., Portela, L., Souza, D., … & Machado-Vieira, R. (2010). Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Progress in Neuro-Psychopharmacology and
31. Biological Psychiatry, 34(6), 819-821. https://doi.org/10.1016/j.pnpbp.2010.02.027
32. Shen, H., Singer, P., Lytle, N., Wei, C., Lan, J., Williams-Karnesky, R., … &Boison, D. (2012). Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. Journal of Clinical Investigation, 122(7), 2567–2577. https://doi.org/10.1172/jci62378

33. Singer, P. and Yee, B. (2023). The adenosine hypothesis of schizophrenia into its third decade: from neurochemical imbalance to early life etiological risks. Frontiers in Cellular Neuroscience, 17. https://doi.org/10.3389/fncel.2023.1120532
34. Steen, N., Dieset, I., Hope, S., Vedal, T., Smeland, O., Matson, W., … &Andreassen, O. (2019). Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. Psychological Medicine, 50(4), 595–606. https://doi.org/10.1017/s0033291719000400
35. Weiser, M., Gershon, A., Rubinstein, K., Petcu, C., Ladea, M., Sima, D., … & Davis, J. (2012). A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research, 138(1), 35-38. https://doi.org/10.1016/j.schres.2012.02.014
36. Zarrinmayeh, H. and Territo, P. (2020). Purinergic receptors of the central nervous system: biology, pet ligands, and their applications. Molecular Imaging, 19. https://doi.org/10.1177/1536012120927609
37. Zhang, R., Zhang, T., Ali, A., Washih, M., Pickard, B., & Watson, D. (2016). Metabolomic profiling of post-mortem brain reveals changes in amino acid and glucose metabolism in mental illness compared with controls. Computational and Structural Biotechnology Journal, 14, 106–116. https://doi.org/10.1016/j.csbj.2016.02.003.